Technology areas: Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
12 pending office actions • 7 clients • 10 examiners • 9 art units • 0 of 12 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
LOWRY BLIXSETH APC focuses on Biotechnology & Pharmaceuticals and has 420 career applications. The profile includes 14 pending office actions, showing an active examination workload within the recorded portfolio.
The resolved allowance rate is 91.41%, and the average number of office actions per allowance is 3.23. The outcome rate indicates that most resolved matters reached allowance, while the action average shows that favorable results have generally required repeated examination responses. For biotechnology and pharmaceutical applicants, the data provide a basis for considering both historical resolution results and the prosecution resources reflected in the docket.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (58%) |
| §102 only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATCHEVES, BASIL S | 2 | 72.4% | +17.2% |
| TUROCY, DAVID P | 2 | 46.9% | +35.8% |
| WOODALL, NICHOLAS W | 1 | 82.1% | +13.3% |
| BATES, DAVID W | 1 | 76.4% | +16.7% |
| GINES, GEORGE SAMUEL | 1 | 71.4% | +41.3% |
| LEE, SHIN | 1 | 75.0% | +100.0% |
| SOSNOWSKI, DAVID E | 1 | 67.4% | +13.2% |
| COHEN, MICHAEL P | 1 | 58.9% | +27.3% |
| COCHRAN, KARI LEE | 1 | 100.0% | +0.0% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19241099 | UNIBODY ORTHOPEDIC SURGICAL INSTRUMENT | WOODALL, NICHOLAS W | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18198240 | UNIVERSAL TIBIAL INSERT WITH ENHANCED MEDIAL CONGRUENCE | COCHRAN, KARI LEE | 22d overdue |
| 19014120 | TRI-LAYER BED COVER | GINES, GEORGE SAMUEL | 23d |
| 17280754 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18427813 | SLAB SUPPORT | KATCHEVES, BASIL S | 49d overdue |
| 19351176 | SLAB SUPPORT | KATCHEVES, BASIL S | 23d overdue |
| 18438087 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | COHEN, MICHAEL P | 8d overdue |
| 19014120 | TRI-LAYER BED COVER | GINES, GEORGE SAMUEL | 23d |
| 19241099 | UNIBODY ORTHOPEDIC SURGICAL INSTRUMENT | WOODALL, NICHOLAS W | — |
| 19208255 | DUAL-PURPOSE ORTHOPEDIC SURGERY INSTRUMENT | BATES, DAVID W | — |
| 19201758 | PROCESSES FOR PRODUCING ORTHOPEDIC IMPLANTS HAVING A SUBSURFACE LEVEL SILICON NITRIDE LAYER APPLIED VIA BOMBARDMENT | TUROCY, DAVID P | — |
| 18983324 | PROCESSES AND SYSTEMS FOR HEADPHONE TUNING | LEE, SHIN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| JOINT DEVELOPMENT, INC. | 5 |
| SafeBoard LLC | 2 |
| Keeco, LLC | 1 |
| Yellow Matter Entertainment, LLC | 1 |
| Neo Able Co., Ltd. | 1 |
| Invion, Inc. | 1 |
| Fabius Biotechnology | 1 |
| Art Unit | Apps |
|---|---|
| 3633 | 2 |
| 1718 | 2 |
| 3673 | 2 |
| 3775 | 1 |
| 3799 | 1 |
| 2695 | 1 |
| 1612 | 1 |
| 3774 | 1 |
| 1654 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19351176 | SLAB SUPPORT | Safeboard LLC | KATCHEVES, BASIL S | 3633 | §103 | Non-Final OA | 23d overdue | Pending | Oct 06, 2025 |
| 19241099 | UNIBODY ORTHOPEDIC SURGICAL INSTRUMENT | Joint Development, Inc. | WOODALL, NICHOLAS W | 3775 | §103 | Non-Final OA | — | Pending | Jun 17, 2025 |
| 19208255 | DUAL-PURPOSE ORTHOPEDIC SURGERY INSTRUMENT | Joint Development, Inc. | BATES, DAVID W | 3799 | §102 | Non-Final OA | — | Pending | May 14, 2025 |
| 19201758 | PROCESSES FOR PRODUCING ORTHOPEDIC IMPLANTS HAVING A SUBSURFACE LEVEL SILICON NITRIDE LAYER APPLIED VIA BOMBARDMENT | Joint Development, Inc. | TUROCY, DAVID P | 1718 | §103DP | Non-Final OA | — | Pending | May 07, 2025 |
| 19014120 | TRI-LAYER BED COVER | Keeco, LLC | GINES, GEORGE SAMUEL | 3673 | §102§103 | Non-Final OA | 23d | Pending | Jan 08, 2025 |
| 18983324 | PROCESSES AND SYSTEMS FOR HEADPHONE TUNING | Yellow Matter Entertainment, LLC | LEE, SHIN | 2695 | §103 | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18871280 | AIR PRESSURE CONTROL DEVICE FOR BEDSORE PREVENTION MATTRESS | Neo Able Co., Ltd. | SOSNOWSKI, DAVID E | 3673 | §103 | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18438087 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | Invion, Inc. | COHEN, MICHAEL P | 1612 | §103 | Final Rejection | 8d overdue | Pending | Feb 09, 2024 |
| 18427813 | SLAB SUPPORT | Safeboard LLC | KATCHEVES, BASIL S | 3633 | §103 | Final Rejection | 49d overdue | Pending | Jan 30, 2024 |
| 18198240 | UNIVERSAL TIBIAL INSERT WITH ENHANCED MEDIAL CONGRUENCE | Joint Development, LLC | COCHRAN, KARI LEE | 3774 | §102§103 | Final Rejection | 22d overdue | Pending | May 16, 2023 |
| 17713791 | PROCESSES FOR PRODUCING ORTHOPEDIC IMPLANTS HAVING A SUBSURFACE LEVEL CERAMIC LAYER APPLIED VIA BOMBARDMENT | Joint Development, LLC | TUROCY, DAVID P | 1718 | §103 | Final Rejection | — | Pending | Apr 05, 2022 |
| 17280754 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | Fabius Biotechnology | D' AMBROSIO, THEA | 1654 | §102§103 | Non-Final OA | — | Pending | Mar 26, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial91.4% of resolved applications prosecuted by Lowry Blixseth Apc were allowed, across 420 applications in USPTO records.
3.23 office actions per allowed application on average.
12 pending office actions as of October 2026, for 7 clients, before 10 examiners in 9 art units.
